<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>ijesm</PublisherName>
      <JournalTitle>International Journal of Engineering, Science and</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>volume 15,issue 5</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>May 2026</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>2026</Year>
        <Month>05</Month>
        <Day>21</Day>
      </PubDate>
      <ArticleType>Engineering, Science and Mathematics</ArticleType>
      <ArticleTitle>Inhalable Budesonide-Loaded Polymeric Nanoparticles for Pulmonary Drug Delivery: Development, Optimization via Quality by Design, and In Vitro Evaluation</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>32</FirstPage>
      <LastPage>47</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Kajal Kandari1* and Ms. Sofiya</FirstName>
          <LastName>Ansari2</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Pulmonary diseases, including asthma and chronic obstructive pulmonary disease (COPD), represent a significant global health burden necessitating effective and targeted therapeutic strategies. Inhaled corticosteroids (ICS), particularly budesonide, remain the cornerstone of anti-inflammatory therapy; however, clinical efficacy is limited by poor lung deposition, rapid mucociliary clearance, low aqueous solubility, and systemic side effects associated with prolonged use. The present study reports the development and optimization of inhalable nanoparticle-based drug delivery systems to overcome these inherent shortcomings.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Budesonide; Pulmonary drug delivery; Polymeric nanoparticles; Nano-in-micro particles; Inhalable dry powder; Nanoprecipitation; Quality by Design (QbD); Central Composite Design; Sustained release; PLGA; Aerodynamic deposition; Chronic respiratory diseases; Asthma; COPD</Keywords>
      <URLs>
        <Abstract>https://www.ijesm.co.in/ubijournal-v1copy/journals/abstract.php?article_id=16253&amp;title=Inhalable Budesonide-Loaded Polymeric Nanoparticles for Pulmonary Drug Delivery: Development, Optimization via Quality by Design, and In Vitro Evaluation</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References/>
      </References>
    </Journal>
  </Article>
</ArticleSet>